A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia
Status:
Completed
Trial end date:
2018-03-15
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and efficacy of ASP1517 compared to
darbepoetin alfa in hemodialysis chronic kidney disease patients with anemia.